FDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma March 9, 2023March 10, 2023 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: FDA accepts supplemental Biologics License…CHMP recommends EU approval of Roche’s Polivy…Roche’s Polivy combination approved by European…Roche presents new and updated data for Polivy in…FDA accepts supplemental Biologics License…Five-year results confirm Roche’s Polivy combination…
